Tag - ARDX

Markets

Cantor ups Ardelyx to OW; PT to $10 ahead of October PDUFA date

Cantor Fitzgerald upgraded Ardelyx (NASDAQ:ARDX) to “overweight” from “neutral” and doubled its price target to $10 from $5, citing an upcoming PDUFA date of Oct. 17 for flagship drug, Xphozah, and higher sales...

August 25, 2023

Markets

Cantor ups Ardelyx PT to $3 after FDA update

Cantor Fitzgerald raised its price target for Ardelyx (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the FDA. The stock closed at $2.51 on Dec. 28. Ardelyx announced that the...

December 29, 2022

Markets

Ladenburg cuts Ardelyx to neutral from buy

Ladenburg Thalmann downgraded Ardelyx (NASDAQ:ARDX) to “neutral” from “buy” and removed its price target, citing an unproductive post-complete response letter (CRL) Type A meeting with the FDA. The stock closed at $1.09...

October 14, 2021

Markets

Cantor halves Ardelyx PT to $7 from $14; maintains OW rating

Cantor Fitzgerald slashed its price target for Ardelyx (NASDAQ:ARDX) to $7 from $14 after the company received a complete response letter from the FDA for its NDA for tenapanor to control serum phosphorus in adult...

July 30, 2021

Tag - ARDX

Cantor ups Ardelyx to OW; PT to $10 ahead of October PDUFA date

Cantor ups Ardelyx PT to $3 after FDA update

Ladenburg cuts Ardelyx to neutral from buy

Cantor halves Ardelyx PT to $7 from $14; maintains OW rating

General

More